Galectin Therapeutics Inc Unit Cons of 2 shs + 1 Wt
(NASDAQ : GALTU)

( )
GALTU PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
Loading GALTU News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
1.64%68.221.0%$511.57m
AMGNAmgen Inc.
-0.06%164.611.2%$473.08m
BIIBBiogen Inc.
-2.41%279.981.2%$433.18m
CELGCelgene Corporation
-0.26%125.201.1%$368.74m
REGNRegeneron Pharmaceuticals, Inc.
-0.25%371.392.7%$306.45m
VRTXVertex Pharmaceuticals Incorporated
-0.79%116.341.8%$289.18m
INCYIncyte Corporation
-1.05%123.082.1%$252.04m
ALXNAlexion Pharmaceuticals, Inc.
0.15%120.731.6%$213.99m
ILMNIllumina, Inc.
1.70%184.583.3%$188.12m
TSROTESARO, Inc.
2.58%142.0115.3%$145.06m
NBIXNeurocrine Biosciences, Inc.
-0.63%53.284.5%$109.21m
BMRNBioMarin Pharmaceutical Inc.
2.00%96.074.3%$103.70m
KITEKite Pharma, Inc.
2.77%82.8015.6%$98.74m
CLVSClovis Oncology, Inc.
1.35%58.6418.2%$88.77m
AAgilent Technologies, Inc.
0.06%54.841.6%$88.10m

Company Profile

Galectin Therapeutics, Inc. operates as a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease and cancer. Its drug candidates are based on the method of targeting galectin proteins, which are key mediators of biologic and pathologic function and its focus is on diseases with serious, life-threatening consequences to patients and those where current treatment options are limited. The company was founded by James C. Czirr and Anatole A. Kltyosov on July 10, 2000 and is headquartered in Norcross, GA.